Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells 15,000 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $20.27, for a total value of $304,050.00. Following the completion of the transaction, the insider owned 364,786 shares of the company’s stock, valued at $7,394,212.22. This represents a 3.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Brian Daniel Webster also recently made the following trade(s):

• On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.60, for a total transaction of $384,000.00.
• On Thursday, January 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.80, for a total transaction of $342,000.00.
• On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $26.59, for a total value of $398,850.00.

Kestra Medical Technologies Trading Down 0.1%

NASDAQ:KMTS traded down $0.02 during trading hours on Thursday, hitting $19.56. 474,831 shares of the company were exchanged, compared to its average volume of 308,765. The stock has a market capitalization of $1.14 billion and a price-to-earnings ratio of -4.94. Kestra Medical Technologies, Ltd. has a one year low of $13.25 and a one year high of $30.00. The company has a fifty day simple moving average of $24.19 and a 200 day simple moving average of $24.53. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.26.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The company had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 74.66%. The business’s revenue for the quarter was up 62.7% on a year-over-year basis.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on KMTS shares. The Goldman Sachs Group set a $24.00 target price on shares of Kestra Medical Technologies in a research report on Friday, January 16th. Stifel Nicolaus set a $30.00 price objective on shares of Kestra Medical Technologies in a research note on Friday, December 12th. BTIG Research reiterated a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Wednesday, December 24th. Finally, Piper Sandler upped their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.00.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of institutional investors and hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies during the 4th quarter valued at $31,000. Russell Investments Group Ltd. increased its stake in Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Kestra Medical Technologies in the third quarter valued at $48,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Kestra Medical Technologies during the second quarter valued at about $54,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.